A Phase I Study of Paclitaxel and Cyclophosphamide in Recurrent Adenocarcinoma of the Ovary

Author： Reed E.   Sarosy G.   Kohn E.   Christian M.   Link Jr C.J.   Goldspiel B.   Davis P.   Jacob J.   Maher M.  

Publisher： Academic Press

ISSN： 0090-8258

Source： Gynecologic Oncology, Vol.61, Iss.3, 1996-06, pp. : 349-353

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Paclitaxel in Patients with Advanced or Recurrent Adenocarcinoma of the Endometrium: A Gynecologic Oncology Group Study

By Ball H.G.   Blessing J.A.   Lentz S.S.   Mutch D.G.  

Gynecologic Oncology, Vol. 62, Iss. 2, 1996-08 ,pp. : 278-281

Academic Press

Access to resources Recommend Favorite

A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer

By Kohn E.C.   Sarosy G.A.   Davis P.   Christian M.   Link C.E.   Ognibene F.P.   Sindelar W.F.   Jacob J.   Steinberg S.M.   Premkumar A.   Reed E.  

Gynecologic Oncology, Vol. 62, Iss. 2, 1996-08 ,pp. : 181-191

Academic Press

Access to resources Recommend Favorite

Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group

By Masuda Norikazu   Taguchi Tetsuya   Nakayama Takahiro   Shiba Eiichi   Watatani Masahiro   Kurebayashi Junichi   Takatsuka Yuichi   Sakamoto Junichi   Noguchi Shinzaburo  

Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. : 989-995

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors

By Campos S.M.   Matulonis U.A.   Penson R.T.   Lee H.   Berkowitz R.S.   Duska L.R.   Fuller A.F.   Wilson K.S.   Puchalski T.A.   Supko J.G.   Seiden M.V.  

Gynecologic Oncology, Vol. 90, Iss. 3, 2003-09 ,pp. : 610-618

Elsevier

Access to resources Recommend Favorite

Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

By Andreopoulou Eleni   Vigoda Ivette   Valero Vicente   Hershman Dawn   Raptis George   Vahdat Linda   Han Hyo   Wright John   Pellegrino Christine   Cristofanilli Massimo   Alvarez Ricardo   Fehn Karen   Fineberg Susan   Sparano Joseph  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 429-435

Springer Publishing Company

Access to resources Recommend Favorite